Nothing Special   »   [go: up one dir, main page]

IL219911A - Anti-c5a binding moieties with high blocking activity - Google Patents

Anti-c5a binding moieties with high blocking activity

Info

Publication number
IL219911A
IL219911A IL219911A IL21991112A IL219911A IL 219911 A IL219911 A IL 219911A IL 219911 A IL219911 A IL 219911A IL 21991112 A IL21991112 A IL 21991112A IL 219911 A IL219911 A IL 219911A
Authority
IL
Israel
Prior art keywords
binding moieties
blocking activity
high blocking
activity
moieties
Prior art date
Application number
IL219911A
Other languages
Hebrew (he)
Other versions
IL219911A0 (en
Original Assignee
Inflarx Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41683202&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL219911(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Inflarx Gmbh filed Critical Inflarx Gmbh
Publication of IL219911A0 publication Critical patent/IL219911A0/en
Publication of IL219911A publication Critical patent/IL219911A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Radiology & Medical Imaging (AREA)
  • Biotechnology (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
IL219911A 2009-11-26 2012-05-21 Anti-c5a binding moieties with high blocking activity IL219911A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26469609P 2009-11-26 2009-11-26
EP09014745A EP2327725A1 (en) 2009-11-26 2009-11-26 Anti-C5a binding moieties with high blocking activity
PCT/EP2010/007197 WO2011063980A1 (en) 2009-11-26 2010-11-26 Anti-c5a binding moieties with high blocking activity

Publications (2)

Publication Number Publication Date
IL219911A0 IL219911A0 (en) 2012-07-31
IL219911A true IL219911A (en) 2017-03-30

Family

ID=41683202

Family Applications (1)

Application Number Title Priority Date Filing Date
IL219911A IL219911A (en) 2009-11-26 2012-05-21 Anti-c5a binding moieties with high blocking activity

Country Status (27)

Country Link
US (4) US8802096B2 (en)
EP (4) EP2327725A1 (en)
JP (4) JP6104605B2 (en)
KR (3) KR20180034690A (en)
CN (2) CN102741283B (en)
AU (1) AU2010324141B2 (en)
BR (1) BR112012012514B1 (en)
CA (1) CA2780520C (en)
CL (1) CL2012001304A1 (en)
CY (2) CY1118463T1 (en)
DK (2) DK3181582T3 (en)
EA (1) EA022759B1 (en)
ES (2) ES2613352T3 (en)
HR (2) HRP20170041T1 (en)
HU (2) HUE049376T2 (en)
IL (1) IL219911A (en)
LT (2) LT3181582T (en)
MX (1) MX2012006060A (en)
NZ (1) NZ600348A (en)
PE (1) PE20130314A1 (en)
PH (1) PH12012501243A1 (en)
PL (2) PL2504362T3 (en)
PT (2) PT2504362T (en)
RS (2) RS59955B1 (en)
SI (2) SI2504362T1 (en)
SM (3) SMT201700054T1 (en)
WO (1) WO2011063980A1 (en)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009041643A1 (en) 2007-09-26 2009-04-02 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in cdr
SG10201608379YA (en) 2008-04-11 2016-11-29 Chugai Pharmaceutical Co Ltd Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
US8703129B2 (en) 2008-09-07 2014-04-22 GlycoNex, Inc. Antibodies against extended type 1 chain antigens, derivatives thereof and use
EP2327725A1 (en) 2009-11-26 2011-06-01 InflaRx GmbH Anti-C5a binding moieties with high blocking activity
DK2563813T3 (en) 2010-04-30 2015-11-30 Alexion Pharma Inc Anti-c5a antibodies and methods of use of antibodies
WO2012073992A1 (en) 2010-11-30 2012-06-07 中外製薬株式会社 Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
EP3524258A1 (en) 2011-06-22 2019-08-14 Apellis Pharmaceuticals, Inc. Methods of treating chronic disorders with complement inhibitors
AU2013222836B2 (en) * 2012-02-20 2017-07-20 Swedish Orphan Biovitrum Ab (Publ) Polypeptides binding to human complement C5
EP2666785A1 (en) * 2012-05-23 2013-11-27 Affiris AG Complement component C5a-based vaccine
MX2016002397A (en) 2013-08-28 2016-09-08 Swedish Orphan Biovitrum Ab (Publ) Stable polypeptides binding to human complement c5.
ES2742505T3 (en) 2013-08-28 2020-02-14 Affibody Ab Binding polypeptides that have a mutated scaffold
US9603927B2 (en) * 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
CN116785426A (en) 2014-03-20 2023-09-22 因弗拉克斯有限责任公司 C5a inhibitors for the treatment of viral pneumonia
MX2017003115A (en) 2014-09-09 2017-11-17 Janssen Biotech Inc Combination therapies with anti-cd38 antibodies.
EA037084B9 (en) 2014-12-04 2021-08-05 Янссен Байотек, Инк. Anti-cd38 antibodies for treatment of acute myeloid leukemia
NZ730607A (en) 2014-12-19 2022-07-01 Chugai Pharmaceutical Co Ltd Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
SI3233921T1 (en) 2014-12-19 2022-01-31 Chugai Seiyaku Kabushiki Kaisha Anti-c5 antibodies and methods of use
MY198983A (en) 2015-05-20 2023-10-06 Janssen Biotech Inc Anti-cd38 antibodies for treatment of light chain amyloidosis and other cd38-positive hematological malignancies
MY192978A (en) 2015-06-22 2022-09-20 Janssen Biotech Inc Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
SI3370770T1 (en) 2015-11-03 2021-03-31 Janssen Biotech, Inc. Subcutaneous formulations of anti-cd38 antibodies and their uses
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
CN106957366B (en) * 2016-01-12 2022-02-01 上海昀怡健康科技发展有限公司 C5aR antibody and preparation method and application thereof
EP3454902A4 (en) * 2016-05-10 2019-10-09 Annexon, Inc. Anti-complement factor c4/c4b antibodies and uses thereof
PT3468990T (en) 2016-06-14 2024-06-25 Regeneron Pharma Anti-c5 antibodies and uses thereof
RU2766112C2 (en) 2016-08-05 2022-02-08 Чугаи Сейяку Кабусики Кайся Composition for prevention or treatment of il-8-related diseases
BR112019018429A2 (en) * 2017-03-06 2020-04-14 Univ Pennsylvania antibody, methods for treating an individual's complement-mediated disease or disorder and for reducing the activity of an individual's complement system, and, cell
SG11201908744PA (en) * 2017-03-23 2019-10-30 Univ Pennsylvania Anti-c5a antibodies and uses thereof
ES2893769T3 (en) * 2017-04-03 2022-02-10 Inflarx Gmbh Treatment of inflammatory diseases with inhibitors of C5a activity
US10376595B2 (en) 2017-04-03 2019-08-13 Inflarx Gmbh Treatment of inflammatory diseases with inhibitors of C5a activity
KR20200020727A (en) 2017-06-23 2020-02-26 인플라알엑스 게엠베하 Treatment of Inflammatory Diseases with Inhibitors of C5a Activity
US11618787B2 (en) 2017-10-31 2023-04-04 Janssen Biotech, Inc. Methods of treating high risk multiple myeloma
WO2019118556A1 (en) 2017-12-13 2019-06-20 Regeneron Pharmaceuticals, Inc. Anti-c5 antibody combinations and uses thereof
EP3586865A1 (en) 2018-06-21 2020-01-01 Charité - Universitätsmedizin Berlin Complement anaphylatoxin binders and their use in treatment of a subject having an ocular wound and/or fibrosis
CN109053882B (en) * 2018-08-28 2019-08-23 东莞市朋志生物科技有限公司 A kind of binding protein of NS1 albumen and application
JP2021536509A (en) 2018-09-06 2021-12-27 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア Humanized anti-C5 antibody and its use
US11773179B2 (en) 2020-01-13 2023-10-03 Visterra, Inc. Antibody molecules to C5aR1 and uses thereof
AU2020438234A1 (en) 2020-03-27 2022-09-29 Inflarx Gmbh Inhibitors of C5a for the treatment of corona virus infection
TW202208427A (en) 2020-05-06 2022-03-01 德商因夫萊亞斯有限公司 Humanized anti-c5a antibodies
WO2021259160A1 (en) * 2020-06-24 2021-12-30 Staidson (Beijing) Biopharmaceuticals Co., Ltd. Antibodies specifically recognizing c5a and uses thereof
AU2022207985A1 (en) 2021-01-13 2023-07-06 Visterra, Inc. Humanized complement 5a receptor 1 antibodies and methods of use thereof
WO2023050233A1 (en) * 2021-09-29 2023-04-06 The Trustees Of The University Of Pennsylvania Humanized anti-c5a antibodies and uses thereof
CN116670288A (en) * 2021-12-22 2023-08-29 舒泰神（北京）生物制药股份有限公司 Isolated anti-C5 a antibody, preparation and application thereof
WO2023186054A1 (en) * 2022-04-02 2023-10-05 舒泰神（北京）生物制药股份有限公司 Antibody specifically recognizing c5a and application of antibody
WO2024245527A1 (en) 2023-05-26 2024-12-05 Inflarx Gmbh Treatment of pneumonia and ards with inhibitors of c5a and il-6 activity
US12180274B2 (en) 2023-05-26 2024-12-31 Inflarx Gmbh Treatment of pneumonia and ARDS with inhibitors of C5a and IL-6 activity

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4704355A (en) 1985-03-27 1987-11-03 New Horizons Diagnostics Corporation Assay utilizing ATP encapsulated within liposome particles
DE3883899T3 (en) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. CHANGED ANTIBODIES.
AU6501390A (en) 1989-09-21 1991-04-18 Synergen, Inc. Method for transporting compositions across the blood brain barrier
ES2284161T3 (en) 1990-01-12 2007-11-01 Amgen Fremont Inc. GENERATION OF XENOGENIC ANTIBODIES.
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6673346B1 (en) * 1999-08-31 2004-01-06 The Regents Of The University Of Michigan Compositions and methods for the treatment of sepsis
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
EP1878441B1 (en) * 2001-08-17 2018-01-24 Genentech, Inc. Complement pathway inhibitors binding to C5 and C5a without preventing the formation of C5b
CA2457461C (en) * 2001-08-17 2013-12-24 Tanox, Inc. Complement pathway inhibitors binding to c5 and c5a without preventing the formation of c5b
US20040110226A1 (en) * 2002-03-01 2004-06-10 Xencor Antibody optimization
JP2005535572A (en) * 2002-04-12 2005-11-24 メディミューン，インコーポレーテッド Recombinant anti-interleukin-9 antibody
EP2327725A1 (en) * 2009-11-26 2011-06-01 InflaRx GmbH Anti-C5a binding moieties with high blocking activity
DK2563813T3 (en) 2010-04-30 2015-11-30 Alexion Pharma Inc Anti-c5a antibodies and methods of use of antibodies

Also Published As

Publication number Publication date
PH12012501243A1 (en) 2012-11-05
HUE049376T2 (en) 2020-09-28
EP3181582B1 (en) 2020-01-29
CN105037541A (en) 2015-11-11
AU2010324141B2 (en) 2014-04-10
US20120231008A1 (en) 2012-09-13
ES2613352T3 (en) 2017-05-24
US9073983B2 (en) 2015-07-07
CY1122674T1 (en) 2021-03-12
EP2327725A1 (en) 2011-06-01
JP2016074721A (en) 2016-05-12
JP2019163266A (en) 2019-09-26
CY1118463T1 (en) 2017-07-12
AU2010324141A1 (en) 2012-06-21
DK2504362T3 (en) 2017-01-30
US9458233B2 (en) 2016-10-04
EA022759B1 (en) 2016-02-29
PE20130314A1 (en) 2013-04-03
EP2504362A1 (en) 2012-10-03
RS55571B1 (en) 2017-05-31
NZ600348A (en) 2014-01-31
LT2504362T (en) 2017-02-10
WO2011063980A1 (en) 2011-06-03
HUE032543T2 (en) 2017-10-30
IL219911A0 (en) 2012-07-31
US20140314772A1 (en) 2014-10-23
EP3670532A1 (en) 2020-06-24
HRP20170041T1 (en) 2017-03-10
KR20190039357A (en) 2019-04-10
KR20120089346A (en) 2012-08-09
EA201200795A1 (en) 2013-04-30
HRP20200241T1 (en) 2020-06-12
DK3181582T3 (en) 2020-02-24
US20170002067A1 (en) 2017-01-05
SMT202000106T1 (en) 2020-03-13
CA2780520A1 (en) 2011-06-03
US10774136B2 (en) 2020-09-15
SI2504362T1 (en) 2017-03-31
JP6591272B2 (en) 2019-10-16
PT3181582T (en) 2020-03-03
PT2504362T (en) 2017-01-18
LT3181582T (en) 2020-02-25
BR112012012514B1 (en) 2022-10-04
CN102741283B (en) 2015-07-15
BR112012012514A2 (en) 2020-07-28
KR102112969B1 (en) 2020-05-19
US20150266949A1 (en) 2015-09-24
MX2012006060A (en) 2012-06-19
SMT201700054T1 (en) 2017-03-08
ES2773725T3 (en) 2020-07-14
CA2780520C (en) 2021-11-23
CL2012001304A1 (en) 2012-08-03
JP2013512209A (en) 2013-04-11
JP6104605B2 (en) 2017-03-29
EP3181582A1 (en) 2017-06-21
KR101844611B1 (en) 2018-04-02
RS59955B1 (en) 2020-03-31
PL3181582T3 (en) 2020-06-01
JP2018080170A (en) 2018-05-24
EP2504362B1 (en) 2016-11-23
KR20180034690A (en) 2018-04-04
SMT201700054B (en) 2017-03-08
PL2504362T3 (en) 2017-08-31
SI3181582T1 (en) 2020-03-31
CN102741283A (en) 2012-10-17
US8802096B2 (en) 2014-08-12

Similar Documents

Publication Publication Date Title
IL219911A0 (en) Anti-c5a binding moieties with high blocking activity
GB2469672B (en) Improved autoinjector
GB201001672D0 (en) Improved autoinjector
PL2490735T3 (en) Autoinjector
GB0913385D0 (en) Improved autoinjector
GB2476367B (en) Syringes
EP2420405A4 (en) Drawer
EP2480084A4 (en) Combination
GB0915319D0 (en) Combination medicament
GB2482515B (en) Blocking bar
EP2480085A4 (en) Combination
GB0916997D0 (en) Combination therapy
GB0919056D0 (en) Toasters
GB0907973D0 (en) Combination therapy
GB0922284D0 (en) Preventing carcinosis
GB0917650D0 (en) Anti[rotozoal activity
GB0903876D0 (en) Spine Safe
GB0918443D0 (en) Autoinjector
GB0921939D0 (en) Syringes
GB201206482D0 (en) #magnotherapy
GB0901902D0 (en) Medicament
GB0903318D0 (en) Medicament

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed